Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines

Ganesh K. Boora, Rahul Kanwar, Amit A. Kulkarni, Josef Pleticha, Matthew Ames, Gary Schroth, Andreas S Beutler, Michaela S. Banck

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Neuroendocrine cancer cell lines are used to investigate therapeutic targets in neuroendocrine tumors (NET) and have been instrumental in the design of clinical trials targeting the PI3K/AKT/mTOR pathways, VEGF inhibitors, and somatostatin analogues. It remains unknown, however, whether the genomic makeup of NET cell lines reflect that of primary NET since comprehensive unbiased genome sequencing has not been performed on the cell lines. Four bronchopulmonary NET (BP-NET)-NCI-H720, NCI-H727, NCI-H835, and UMC11-and two pancreatic neuroendocrine tumors (panNET)-BON-1 and QGP1-were cultured. DNA was isolated, and exome sequencing was done. GATK and EXCAVATOR were used for bioinformatic analysis. We detected a total of 1,764 nonsynonymous single nucleotide variants at a rate of 8 per Mb in BP-NET and 4.3 per Mb in panNET cell lines, including 52 mutated COSMIC cancer genes in these cell lines, such as TP53, BRCA1, RB1, TSC2, NOTCH1, EP300, GNAS, KDR, STK11, and APC but not ATRX, DAXX, nor MEN1. Our data suggest that mutation rate, the pattern of copy number variations, and the mutational spectra in the BP-NET cell lines are more similar to the changes observed in small cell lung cancer than those found in primary BP-NET. Likewise, mutation rate and pattern including the absence of mutations in ATRX/DAXX, MEN1, and YY1 in the panNET cell lines BON1 and QGP1 suggest that these cell lines do not have the genetic signatures of a primary panNET. These results suggest that results from experiments with BP-NET and panNET cell lines need to be interpreted with caution.

Original languageEnglish (US)
Pages (from-to)374-381
Number of pages8
JournalCancer genetics
Volume208
Issue number7-8
DOIs
StatePublished - Jul 1 2015

Fingerprint

Exome
Neuroendocrine Tumors
Tumor Cell Line
Neuroendocrine Cells
Cell Line
Multiple Endocrine Neoplasia Type 1
Mutation Rate
Neoplasm Genes
Small Cell Lung Carcinoma
Somatostatin
Computational Biology
Phosphatidylinositol 3-Kinases
Vascular Endothelial Growth Factor A
Nucleotides
Clinical Trials
Genome
Mutation

Keywords

  • Bronchopulmonary carcinoid
  • Cell lines
  • Exome
  • Next-generation sequencing
  • Pancreatic neuroendocrine tumor

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Boora, G. K., Kanwar, R., Kulkarni, A. A., Pleticha, J., Ames, M., Schroth, G., ... Banck, M. S. (2015). Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines. Cancer genetics, 208(7-8), 374-381. https://doi.org/10.1016/j.cancergen.2015.04.002

Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines. / Boora, Ganesh K.; Kanwar, Rahul; Kulkarni, Amit A.; Pleticha, Josef; Ames, Matthew; Schroth, Gary; Beutler, Andreas S; Banck, Michaela S.

In: Cancer genetics, Vol. 208, No. 7-8, 01.07.2015, p. 374-381.

Research output: Contribution to journalArticle

Boora, GK, Kanwar, R, Kulkarni, AA, Pleticha, J, Ames, M, Schroth, G, Beutler, AS & Banck, MS 2015, 'Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines', Cancer genetics, vol. 208, no. 7-8, pp. 374-381. https://doi.org/10.1016/j.cancergen.2015.04.002
Boora, Ganesh K. ; Kanwar, Rahul ; Kulkarni, Amit A. ; Pleticha, Josef ; Ames, Matthew ; Schroth, Gary ; Beutler, Andreas S ; Banck, Michaela S. / Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines. In: Cancer genetics. 2015 ; Vol. 208, No. 7-8. pp. 374-381.
@article{063f5e6c1ca84608a04d0d2e4a392cd8,
title = "Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines",
abstract = "Neuroendocrine cancer cell lines are used to investigate therapeutic targets in neuroendocrine tumors (NET) and have been instrumental in the design of clinical trials targeting the PI3K/AKT/mTOR pathways, VEGF inhibitors, and somatostatin analogues. It remains unknown, however, whether the genomic makeup of NET cell lines reflect that of primary NET since comprehensive unbiased genome sequencing has not been performed on the cell lines. Four bronchopulmonary NET (BP-NET)-NCI-H720, NCI-H727, NCI-H835, and UMC11-and two pancreatic neuroendocrine tumors (panNET)-BON-1 and QGP1-were cultured. DNA was isolated, and exome sequencing was done. GATK and EXCAVATOR were used for bioinformatic analysis. We detected a total of 1,764 nonsynonymous single nucleotide variants at a rate of 8 per Mb in BP-NET and 4.3 per Mb in panNET cell lines, including 52 mutated COSMIC cancer genes in these cell lines, such as TP53, BRCA1, RB1, TSC2, NOTCH1, EP300, GNAS, KDR, STK11, and APC but not ATRX, DAXX, nor MEN1. Our data suggest that mutation rate, the pattern of copy number variations, and the mutational spectra in the BP-NET cell lines are more similar to the changes observed in small cell lung cancer than those found in primary BP-NET. Likewise, mutation rate and pattern including the absence of mutations in ATRX/DAXX, MEN1, and YY1 in the panNET cell lines BON1 and QGP1 suggest that these cell lines do not have the genetic signatures of a primary panNET. These results suggest that results from experiments with BP-NET and panNET cell lines need to be interpreted with caution.",
keywords = "Bronchopulmonary carcinoid, Cell lines, Exome, Next-generation sequencing, Pancreatic neuroendocrine tumor",
author = "Boora, {Ganesh K.} and Rahul Kanwar and Kulkarni, {Amit A.} and Josef Pleticha and Matthew Ames and Gary Schroth and Beutler, {Andreas S} and Banck, {Michaela S.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.cancergen.2015.04.002",
language = "English (US)",
volume = "208",
pages = "374--381",
journal = "Cancer genetics",
issn = "2210-7762",
publisher = "Elsevier BV",
number = "7-8",

}

TY - JOUR

T1 - Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines

AU - Boora, Ganesh K.

AU - Kanwar, Rahul

AU - Kulkarni, Amit A.

AU - Pleticha, Josef

AU - Ames, Matthew

AU - Schroth, Gary

AU - Beutler, Andreas S

AU - Banck, Michaela S.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Neuroendocrine cancer cell lines are used to investigate therapeutic targets in neuroendocrine tumors (NET) and have been instrumental in the design of clinical trials targeting the PI3K/AKT/mTOR pathways, VEGF inhibitors, and somatostatin analogues. It remains unknown, however, whether the genomic makeup of NET cell lines reflect that of primary NET since comprehensive unbiased genome sequencing has not been performed on the cell lines. Four bronchopulmonary NET (BP-NET)-NCI-H720, NCI-H727, NCI-H835, and UMC11-and two pancreatic neuroendocrine tumors (panNET)-BON-1 and QGP1-were cultured. DNA was isolated, and exome sequencing was done. GATK and EXCAVATOR were used for bioinformatic analysis. We detected a total of 1,764 nonsynonymous single nucleotide variants at a rate of 8 per Mb in BP-NET and 4.3 per Mb in panNET cell lines, including 52 mutated COSMIC cancer genes in these cell lines, such as TP53, BRCA1, RB1, TSC2, NOTCH1, EP300, GNAS, KDR, STK11, and APC but not ATRX, DAXX, nor MEN1. Our data suggest that mutation rate, the pattern of copy number variations, and the mutational spectra in the BP-NET cell lines are more similar to the changes observed in small cell lung cancer than those found in primary BP-NET. Likewise, mutation rate and pattern including the absence of mutations in ATRX/DAXX, MEN1, and YY1 in the panNET cell lines BON1 and QGP1 suggest that these cell lines do not have the genetic signatures of a primary panNET. These results suggest that results from experiments with BP-NET and panNET cell lines need to be interpreted with caution.

AB - Neuroendocrine cancer cell lines are used to investigate therapeutic targets in neuroendocrine tumors (NET) and have been instrumental in the design of clinical trials targeting the PI3K/AKT/mTOR pathways, VEGF inhibitors, and somatostatin analogues. It remains unknown, however, whether the genomic makeup of NET cell lines reflect that of primary NET since comprehensive unbiased genome sequencing has not been performed on the cell lines. Four bronchopulmonary NET (BP-NET)-NCI-H720, NCI-H727, NCI-H835, and UMC11-and two pancreatic neuroendocrine tumors (panNET)-BON-1 and QGP1-were cultured. DNA was isolated, and exome sequencing was done. GATK and EXCAVATOR were used for bioinformatic analysis. We detected a total of 1,764 nonsynonymous single nucleotide variants at a rate of 8 per Mb in BP-NET and 4.3 per Mb in panNET cell lines, including 52 mutated COSMIC cancer genes in these cell lines, such as TP53, BRCA1, RB1, TSC2, NOTCH1, EP300, GNAS, KDR, STK11, and APC but not ATRX, DAXX, nor MEN1. Our data suggest that mutation rate, the pattern of copy number variations, and the mutational spectra in the BP-NET cell lines are more similar to the changes observed in small cell lung cancer than those found in primary BP-NET. Likewise, mutation rate and pattern including the absence of mutations in ATRX/DAXX, MEN1, and YY1 in the panNET cell lines BON1 and QGP1 suggest that these cell lines do not have the genetic signatures of a primary panNET. These results suggest that results from experiments with BP-NET and panNET cell lines need to be interpreted with caution.

KW - Bronchopulmonary carcinoid

KW - Cell lines

KW - Exome

KW - Next-generation sequencing

KW - Pancreatic neuroendocrine tumor

UR - http://www.scopus.com/inward/record.url?scp=84939468689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939468689&partnerID=8YFLogxK

U2 - 10.1016/j.cancergen.2015.04.002

DO - 10.1016/j.cancergen.2015.04.002

M3 - Article

VL - 208

SP - 374

EP - 381

JO - Cancer genetics

JF - Cancer genetics

SN - 2210-7762

IS - 7-8

ER -